Physician profile
Steven A Thau
NPI 1750312955
$5,792.95
in general payments reported to CMS, 2019-2025
23 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.47 · 2020: $1,308 · 2021: $1,410 · 2022: $495 · 2023: $336 · 2024: $1,125 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,253 · Consulting Fee: $150 · Education: $80.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,252.71 |
| Consulting Fee | $150.00 |
| Education | $80.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $1,250.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $891.78 | 2022-2025 | Tezspire, Fasenra, Tagrisso |
| Olympus Corporation of The Americas | $808.46 | 2020 | |
| Glaxosmithkline, LLC. | $528.55 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Midmark Corporation | $500.00 | 2020 | |
| Genzyme Corporation | $368.29 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $316.99 | 2022-2025 | |
| United Therapeutics Corporation | $304.84 | 2019-2025 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.24 | 2025 | |
| Mylan Specialty L.P. | $106.32 | 2024 | Yupelri |
| Baxter Healthcare | $102.45 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Novartis Pharmaceuticals Corporation | $97.57 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Electromed, INC. | $52.49 | 2025 | Smartvest |
| Philips North America LLC | $47.80 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $34.78 | 2021-2022 | |
| Amgen INC. | $34.47 | 2024-2025 | Tezspire |
| Abbvie INC. | $25.21 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $23.61 | 2025 | Dupixent |
| Pfizer INC. | $21.41 | 2025 | |
| Gilead Sciences, INC. | $18.42 | 2021 | |
| Novo Nordisk INC | $16.82 | 2025 | Ozempic, Rybelsus |
| Advanced Respiratory, INC | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Thau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.